TICKERNERD
Menu
KYTXKYTXHealthcare · Biotechnology

KYTX Stock Forecast: Kyverna Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$5.85
−0.68% on the day

The 6 Wall Street analysts covering Kyverna Therapeutics, Inc. hold a median 12-month price target of $32 — +447.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$364.3M
Ticker Nerd rank
36/ 100
Median analyst target
$32
Analysts covering
6
Revenue$0.0
Operating income−$39.6M
Net income−$38.3M
Free cash flow−$40.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.1%
1M
−14.5%
YTD
−37.8%
1Y
−18.4%
From 52W high
−48.0%
From 52W low
+11.0%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KYTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kyverna Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
36/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
78
Revisions
64
Size
57
Momentum
57
Accruals
48
Value
31
Quality
28
Volatility
20
Issuance
10

Growth (78): Sales and profits are climbing, and climbing faster than before.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KYTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KYTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26KYTXHigh $33Median $32Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $25Median $32High $33

The green dot is the last close — the median target sits +447.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 June 2026HC Wainwright & Co.ReiteratesBuy$25
15 May 2026HC Wainwright & Co.MaintainsBuy—
13 May 2026JP MorganMaintainsOverweight—
23 Apr 2026HC Wainwright & Co.ReiteratesBuy—
16 Dec 2025Wells FargoMaintainsOverweight—
4 Dec 2025Morgan StanleyMaintainsOverweight—
30 Oct 2025Wells FargoMaintainsOverweight—
27 Oct 2025HC Wainwright & Co.MaintainsBuy—
8 Oct 2025Wells FargoMaintainsOverweight—
29 Aug 2025HC Wainwright & Co.MaintainsBuy—
20 Aug 2025William BlairInitiatesOutperform—
27 May 2025HC Wainwright & Co.UpgradeBuy—
3 Apr 2025HC Wainwright & Co.MaintainsNeutral—
1 Apr 2025Morgan StanleyMaintainsOverweight—
20 Nov 2024HC Wainwright & Co.MaintainsNeutral—
15 Nov 2024Wells FargoMaintainsOverweight—
10 Oct 2024UBSInitiatesBuy—
19 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024HC Wainwright & Co.MaintainsNeutral—
31 July 2024JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KYTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KYTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Kyverna Therapeutics, Inc. returned −18.4% against +13.1% for the S&P 500, dividends included.

KYTX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26KYTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KYTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

Kyverna Therapeutics, Inc. (KYTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.6×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
2.2×

Cheaper than 44% of US stocks

EV / EBITDA
−1.3×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−87.2%

Higher than 15% of US stocks

Return on assets
−44.5%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kyverna Therapeutics, Inc. (KYTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kyverna Therapeutics, Inc. has a market value of $364.3M and an enterprise value of $197.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$152.6M.

  • Diluted earnings per share, trailing twelve months: $−2.94.

  • Free cash flow in the twelve months to 30 June 2026: −$160.2M.

  • Shares outstanding: 61.6M.

  • Trailing P/E: −1.6×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Kyverna Therapeutics, Inc. employs 149 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

KYTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KYTXKyverna Therapeutics, Inc.$364.3M36
GALTGalectin Therapeutics, Inc.$357.0M69
CTNMContineum Therapeutics, Inc.$354.6M32
CAPRCapricor Therapeutics, Inc.$358.3M17
RLMDRelmada Therapeutics, Inc.$351.4M64
SPRYARS Pharmaceuticals, Inc.$360.8M9
OBIOOrchestra Biomed Holdings, Inc.$350.5M44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kyverna Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KYTX news & analysis

Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026

GlobeNewsWire · 23 Oct 2026positive

Kyverna Therapeutics highlighted updated clinical data for miv-cel in progressive multiple sclerosis at MS Toronto 2026. The company said a single dose showed CNS CAR T-cell penetration and improved disability scores, while removing the need for chronic immunotherapies.

Why it matters — The update provides KYTX watchers with information about miv-cel’s reported clinical effects in progressive multiple sclerosis.

Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 22 Oct 2026neutral

A PRNewsWire item encourages Kyverna Therapeutics shareholders to contact a firm to discuss their rights and options at no cost or obligation. It says the firm would handle any matter on a contingent-fee basis, with no out-of-pocket legal fees or expenses for shareholders.

Why it matters — KYTX watchers may note the shareholder-rights outreach, though the excerpt does not provide details of any alleged fiduciary-duty breach.

Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto

GlobeNewsWire · 21 Oct 2026positive

Kyverna Therapeutics presented the full one-year registrational data set for miv-cel in stiff person syndrome at MS Toronto. The company reported sustained clinical benefit across all primary and secondary endpoints, with nearly all patients remaining off chronic immunotherapies.

Why it matters — The one-year findings provide KYTX watchers with an update on miv-cel’s reported durability of clinical benefit in stiff person syndrome.

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

GlobeNewsWire · 7 Oct 2026positive

Kyverna Therapeutics announced that two abstracts were selected for presentation at the MSToronto2026 joint ACTRIMS-ECTRIMS meeting. The presentations will include one-year KYSA-8 results in stiff person syndrome and updated Phase 1 data in progressive multiple sclerosis, with the excerpt describing sustained clinical benefit and well-tolerated safety profiles.

Why it matters — The presentations will provide KYTX watchers with clinical-trial updates across two neurologic autoimmune disease programs.

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript

Seeking Alpha · 24 Sept 2026positive

Kyverna Therapeutics discussed positive topline data and longer-term follow-up results from its SPS (stiff person syndrome) and GMG (generalized myasthenia gravis) trials, as covered in a Seeking Alpha transcript of the discussion.

Why it matters — KYTX watchers would follow this because positive trial data and longer-term follow-up outcomes for SPS and GMG bear on the company's clinical pipeline progress.

FAQ

Frequently asked questions about KYTX stock

What is the KYTX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Kyverna Therapeutics, Inc. have a median 12-month price target of $32, with estimates ranging from $25 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KYTX stock a buy right now?

Of the 6 analysts covering Kyverna Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kyverna Therapeutics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KYTX?

As at 28 Oct 2026, Kyverna Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (78 of 100).

Will KYTX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +447.0% from the last close, and Ticker Nerd's factor model ranks Kyverna Therapeutics, Inc. 36 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KYTX stock forecast for 2030?

No analyst covering Kyverna Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $33 over the next 12 months.

How has KYTX stock performed over the past year?

Kyverna Therapeutics, Inc. returned -18.4% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kyverna Therapeutics, Inc. do?

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases.

What is the latest news on KYTX?

The most recent item we track (GlobeNewsWire, 23 Oct 2026): "Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026". Kyverna Therapeutics highlighted updated clinical data for miv-cel in progressive multiple sclerosis at MS Toronto 2026. The company said a single dose showed CNS CAR T-cell penetration and improved disability scores, while removing the need for chronic immunotherapies.

Company

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company’s work centers on engineered T-cell therapies, including CAR T-cell and related cell therapy approaches designed to target the immune cells that drive severe autoimmune and inflammatory conditions. Its current programs span multiple therapeutic areas, with particular emphasis on rheumatology and neurology, alongside research efforts in other antibody-mediated and inflammatory diseases. Kyverna Therapeutics develops product candidates for conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, stiff person syndrome, multiple sclerosis, and inflammatory bowel disease. The company’s platform combines advanced cell engineering and synthetic biology to pursue more precise immune modulation than traditional broad immunosuppressive treatments. Headquartered in Emeryville, California, Kyverna Therapeutics plays a specialized role in the biotechnology market by advancing cell-based immunology therapies for serious unmet medical needs.

CEO Mr. Warner Biddle · 149 employees · United States · https://kyvernatx.com